SyMRI to be studied as a technology to characterize brain tumors

SyntheticMR and The University of Texas MD Anderson Cancer Center have signed a research agreement to study SyMRI to characterize brain tumors.

SyMRI provides quantitative information including tissue segmentation and T1, T2 and PD-maps, thus adding objective data to the MRI exam. The technology will be studied for its potential to add diagnostic value for various clinical applications including characterization of brain tumors.

SyMRI IMAGE generates multiple contrast images from a single 3 to 6 minutes scan, thus allowing a significant reduction in scan time compared to serial acquisition of each contrast image separately. Parameters are also adjustable post scan, enabling both fine tuning of images as well as recreation of additional contrasts. SyMRI NEURO adds quantitative data and automatic segmentation of brain tissue for efficient analysis and objective decision making. The agreement with MD Anderson includes a license of SyMRI IMAGE and SyMRI NEURO for research use at the hospital. SyMRI is CE-marked for clinical use in Europe but SyMRI is not available for clinical use in the USA.

Source: SyMRI

24.11.2015

News • New sequencing technique

Classifying pediatric brain tumors with liquid biopsy and AI

Clues in the CSF: Researchers have developed the first high-precision method that can theoretically diagnose common brain tumors in children and adolescents without surgery.

News • Machine learning prediction

AI opens non-surgical way to detect brain cancer metastasis

Researchers have developed an artificial intelligence (AI) model to detect the spread of metastatic brain cancer using MRI scans, offering insights into patients’ cancer without aggressive surgery.

News • New therapy approach for brain tumors

Attacking glioblastoma from multiple angles

A new approach to fight glioblastoma: Swiss researchers have now developed an immunotherapy that not only attacks the brain tumor—it also turns its microenvironment against it.